Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

miR-208a as a biomarker of isoproterenol-induced cardiac injury in Sod2+/- and C57BL/6J wild-type mice.

Liu L, Aguirre SA, Evering WE, Hirakawa BP, May JR, Palacio K, Wang J, Zhang Y, Stevens GJ.

Toxicol Pathol. 2014 Oct;42(7):1117-29. doi: 10.1177/0192623314525684. Epub 2014 Apr 8.

PMID:
24713317
2.

Responses of the steroidogenic pathway from exposure to methyl-tert-butyl ether and tert-butanol.

de Peyster A, Mihaich E, Kim DH, Elyea WA, Nemec MJ, Hirakawa BP, Leggieri SE.

Toxicology. 2014 May 7;319:23-37. doi: 10.1016/j.tox.2014.01.015. Epub 2014 Feb 19.

3.

First-in-class pan caspase inhibitor developed for the treatment of liver disease.

Linton SD, Aja T, Armstrong RA, Bai X, Chen LS, Chen N, Ching B, Contreras P, Diaz JL, Fisher CD, Fritz LC, Gladstone P, Groessl T, Gu X, Herrmann J, Hirakawa BP, Hoglen NC, Jahangiri KG, Kalish VJ, Karanewsky DS, Kodandapani L, Krebs J, McQuiston J, Meduna SP, Nalley K, Robinson ED, Sayers RO, Sebring K, Spada AP, Ternansky RJ, Tomaselli KJ, Ullman BR, Valentino KL, Weeks S, Winn D, Wu JC, Yeo P, Zhang CZ.

J Med Chem. 2005 Nov 3;48(22):6779-82.

PMID:
16250635
4.

Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor.

Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC.

J Pharmacol Exp Ther. 2004 May;309(2):634-40. Epub 2004 Jan 23.

PMID:
14742742
5.

Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury.

Hoglen NC, Hirakawa BP, Fisher CD, Weeks S, Srinivasan A, Wong AM, Valentino KL, Tomaselli KJ, Bai X, Karanewsky DS, Contreras PC.

J Pharmacol Exp Ther. 2001 May;297(2):811-8.

PMID:
11303074

Supplemental Content

Loading ...
Support Center